Identifier |
20210222_nanos_sciplatform1_03-video |
Title |
Teprotumumab Efficacy in Retreatment and Longer-Term Thyroid Eye Disease: OPTIC-X Study Results |
Creator |
Raymond Douglas, Saba Sile, Terry Smith, George Kahaly |
Subject |
Neuro-ophth & Systemic Disease (eg. MS, MG, Thyroid); Orbit |
Description |
Teprotumumab, an insulin-like growth factor I receptor inhibitory antibody, improves proptosis, diplopia, inflammatory signs/symptoms, and quality of life in thyroid eye disease (TED) patients.1,2 In the phase 3, randomized, placebo-controlled trial (OPTIC), 83% receiving teprotumumab were responders (≥2 mm proptosis reduction) after 24 weeks (vs. 10% placebo).2 Extension of this trial (OPTIC-X) examined benefit of retreatment (additional 24-week treatment) in those who had disease exacerbation (flare) or were placebo/teprotumumab non-responders, and whether longer disease duration impacts treatment response. |
Date |
2021-02 |
Language |
eng |
Format |
video/mp4 |
Type |
Image/MovingImage |
Source |
2021 North American Neuro-Ophthalmology Society Annual Meeting |
Relation is Part of |
NANOS Annual Meeting 2021: Scientific Platform I |
Collection |
Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu |
Publisher |
Spencer S. Eccles Health Sciences Library, University of Utah |
Holding Institution |
North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416 |
Rights Management |
Copyright 2021. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright |
ARK |
ark:/87278/s6tr20r5 |
Context URL |
The NANOS Annual Meeting Neuro-Ophthalmology Collection: https://novel.utah.edu/collection/NAM/toc/ |
Contributor Primary |
Raymond Douglas |
Contributor Secondary |
Saba Sile, Terry Smith, George Kahaly |
Setname |
ehsl_novel_nam |
ID |
1697215 |
Reference URL |
https://collections.lib.utah.edu/ark:/87278/s6tr20r5 |